All In Biotech

Drug Trial Radar · NCT07610798

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

A Phase I/II, Open-Label, Multi-Center, Dose Escalation and Cohort Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

178

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

May 2029

Study completion May 2029

Sponsor

Sponsor type
Industry
First posted
May 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.

Conditions

  • Advance Solid Tumors
  • Colon and Rectal Cancer
  • Non - Small Cell Lung Cancer NSCLC
  • Pancreatic Adenocarcinoma Advanced or Metastatic
  • Ovarian Cancer
  • Endometrial Cancer
  • Biliary Cancers

Interventions

  • INV-8989Drug

    INV-8989 is admistered once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of participants with treatment-emergent adverse events (TEAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0Time frame: 12 months
  2. Phase 1: Maximum tolerated dose (MTD)Time frame: Within first 21 days of treatment
  3. Phase 1: Recommended dose range (RDR) and/or Recommended Phase Ⅱ dose (RP2D)Time frame: 12 months
  4. Phase 2: Evaluate overall response rate (ORR)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.